Ads
related to: Acute Myeloid Leukemia- Side Effects & Safety
Learn About Possible Side Effects
You May Experience During Treatment
- Understanding Ph+ CML-CP
Patients With The T315I Mutation,
Learn About A Treatment Option.
- Ph+ CML-CP Treatment
Visit The Patient Website To
Learn More About This Treatment.
- Treatment Challenges
Patients, Learn About Setting
Goals & Reaching Milestones.
- Side Effects & Safety
Search results
On National Historic Marker Day, meet the CNY man whose plaques celebrate history in 49 states
The Post-Standard· 7 hours agoAn imposing physical stature and a charisma to match, you would not know it to look at the self-made...
‘Potter Strong’ fundraiser in honor of the late Rochelle Potter
WFXR Roanoke via Yahoo Sports· 14 hours agoROANOKE, Va. (WFXR) — In a follow-up to a story we brought you back in January on Patrick Henry...
Hemogenyx Pharmaceuticals outlines significant progress with HEMO-CAR-T in 2023
Proactive Investors· 4 hours agoAfter re-manufacturing the lentivirus, Hemogenyx successfully addressed the FDA's concerns and...
HanxBio announces the publication of a research paper in Scientific Reports on preclinical...
FOX 59 Indianapolis· 3 days agoHanxBio today announced that it has published a research article titled "Narazaciclib, a novel...
FDA grants breakthrough status for Kura Oncology's AML drug candicate By Investing.com
Investing.com· 4 days agoFood and Drug Administration (FDA) has awarded Breakthrough Therapy Designation to its drug...
Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases
BioPharma Dive via Yahoo Finance· 4 days agoNonetheless, several have drawn the interest of large pharmaceutical companies. Ipsen, for instance,...
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Investor's Business Daily· 1 day agoThat could be why the first generation of radiopharmaceuticals were flops, Seth, the Actinium CEO,...
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
Morningstar· 4 days agoFood and Drug Administration (FDA) for the treatment of patients with relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML ...
Study reveals insights into DDX41 protein's role in blood cancer pathogenesis
Medical Xpress· 3 days agoA study led by Professors Hongtae Kim and JaYil Lee from the Department of Biological Sciences, in collaboration with researchers from the Catholic University of Korea, sheds light on the pivotal ...
Deverra Therapeutics Granted FDA Fast Track Designation for DVX101
Digital Journal· 2 days agoDesignation Validates Preliminary Data and Supports Accelerated Drug Development SEATTLE, WA / ACCESSWIRE / April 24, 2024 / Deverra Therapeutics, Inc., a clinical-stage biotechnology company ...
Ads
related to: Acute Myeloid Leukemia